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This prospective, double-blind trial assessed whether the addition of a glycopeptide would be able to reduce
the time to defervescence in neutropenic patients with cancer who had persistent fever 48–60 h after the
initiation of empirical piperacillin-tazobactam monotherapy. Of 763 eligible patients, 165 with persistent fever
were randomized to receive piperacillin-tazobactam therapy plus either vancomycin therapy or placebo. De-
fervescence was observed in 82 (95%) of 86 patients in the vancomycin group and in 73 (92%) of 79 patients
in the placebo group ( ). The distributions of the time to defervescence were not statistically significantPp .52
between the 2 groups (estimated hazard ratio, 1.03; 95% confidence interval, 0.75–1.43; ). The numberPp .75
of additional episodes of gram-positive bacteremia and the percentage of patients for whom amphotericin B
was empirically added to their therapy regimen were also similar in both groups. This study failed to dem-
onstrate that the empirical addition of vancomycin therapy to the treatment regimen is of benefit to persistently
febrile neutropenic patients with cancer.
Therapeutic changes are a common clinical practice for
granulocytopenic patients with cancer and persistent
fever, despite the absence of clinical deterioration and/
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or documented infection with a microorganism resis-
tant to the allocated regimen. In 3 large trials assessing
the efficacy of meropenem or ceftazidime monotherapy,
the most frequent treatment modification was the ad-
dition of a glycopeptide antibiotic (i.e., vancomycin or
teicoplanin) after 3–4 days of empirical therapy, mainly
for the treatment of persistent fever [1–3]. However, to
date, no study has documented that this practice is of
any benefit to such patients. In addition, the indiscrim-
inate administration of glycopeptides is expensive and
might lead to increased resistance among staphylococci
and enterococci, which would in itself have major clin-
ical implications [4].
Because the addition of vancomycin did not reduce
mortality in any previous study and was primarily jus-
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tified by the presence of persistent fever, the primary objective
of this prospective, randomized, multicenter, double-blind trial
was to assess whether the addition of a glycopeptide would be
able to reduce the time to defervescence in neutropenic patients
who had persistent fever 48–60 h after the initiation of empirical
piperacillin-tazobactam (P-T) monotherapy [5–7]. The choice
of P-T as the initial monotherapy was based both on data that
showed that administration of empirical monotherapy is fea-
sible for febrile granulocytopenic patients and on results of in
vitro susceptibility testing of bacteria, which caused bacteremia
in neutropenic patients randomized in our previous trials, that
showed that P-T has the potential to be effective in the man-
agement of these infections [1–3, 8–10].
PATIENTS AND METHODS
Eligibility criteria. This trial comprised patients from 34
centers of the International Antimicrobial Therapy Group of
the European Organisation for Research on Treatment of Can-
cer (EORTC-IATG) located in Europe, the Middle East, and
North America. Febrile granulocytopenic patients with cancer
were enrolled in the trial if they met the following inclusion
criteria: (1) a diagnosis of leukemia, lymphoma, or Hodgkin
disease or receipt of a stem cell or bone marrow transplant
(allogenic or autologous) for the treatment of neoplastic dis-
ease; (2) an absolute granulocyte count of 1000 cells/mm3,
which was anticipated to decrease to !500 cells/mm3 within
24–48 h and was expected to remain at this level for 17 days
after the onset of fever; (3) a fever (oral or axillary temperature,
38.5C [101.3F] once, or 138C [100.4F] on 2 occasions
separated at least by 1 h during a 12-h period); and (4) had
presumed bacterial infection. Exclusion criteria were as follows:
age of !2 years; receipt of intravenous antibacterial agent within
4 days before the initiation of study; known allergy to any of
the antibiotics used in this trial; previous inclusion in the study;
renal failure requiring hemodialysis or peritoneal dialysis, se-
rum creatinine level of 1200 mmol/L or 2.25 mg/dL or estimated
creatinine clearance of !40 mL/min in adult patients; high
probability of death within 48 h; and documented catheter-
related infection, presence of lung infiltrate, pregnancy, or
known HIV infection.
In case of persistent fever (defined as an oral or axillary tem-
perature of 138C twice in the previous 12 h or of 138.5C once),
patients were randomized to receive either vancomycin therapy
or placebo in addition to P-T therapy, provided that they had
persistent neutropenia and had received a diagnosis of possible
infection (fever of unknown origin), clinically documented in-
fection, or microbiologically documented infection due to P-
T–susceptible gram-positive bacteria (such as methicillin-sus-
ceptible staphylococci, streptococci, or enterococci). Patients
were not randomized if they were no longer febrile or neutro-
penic or if they had persistent fever and 1 of the following con-
ditions present at initial enrollment (i.e., onset of fever): micro-
biologically documented infection due to gram-negative bacteria;
microbiologically documented infection due to P-T–resistant
gram-positive bacteria (e.g., methicillin-resistant staphylococci or
penicillin-resistant streptococci); microbiologically documented
viral, fungal, or mixed infection; clinically documented catheter-
related infection; or a documented lung infiltrate.
Enrollment and randomization procedures. All patients
who fulfilled the inclusion criteria received P-T therapy. Then,
between 48 and 60 h later, if the patient was persistently febrile
and neutropenic, the investigator checked whether the patient
was eligible for randomization into the vancomycin-placebo
trial. Data for both initial enrollment and subsequent random-
ization were centralized at the EORTC-IATG Data Center in
Brussels, as previously described [11]. Data for treatment al-
location was computerized, and randomization was dynami-
cally performed after the application of a randomization al-
gorithm, which used the minimization technique of a global
imbalances function between the 2 treatment arms, with the
following 3 stratification variables: name and location of study
center, infection documentation at randomization, and under-
lying disease (i.e., any cancer that required bone marrow trans-
plantation, such as leukemia, lymphoma, or Hodgkin disease).
Hypotheses and statistical considerations. The primary
objective of the trial was to compare the overall distribution
of the time to defervescence between granulocytopenic patients
with cancer and persistent fever who were initially treated with
P-T and randomized to receive vancomycin therapy and those
randomized to receive placebo. We estimated that the addition
of vancomycin therapy should have decreased the febrile period
by at least 36 h to be clinically meaningful. To determine the
required sample size, we assumed that the ratio of the risks of
defervescence (hazard ratio) did not change with time. We
estimated that the study should be powered such as to reject
the hypothesis that there was no significant difference in the
time to defervescence between the 2 arms, given a hazard ratio
of 1.6. This value of 1.6 was based on an expected median
additional time to defervescence of 96 h in the placebo group
(according to a previous trial [12]) and on a reduction in the
additional time to defervescence of 36 h in the vancomycin
group. Thus, using a 2-tailed log-rank test with the assumption
of ∼20% of censored data, we calculated that 113 assessable
patients per arm would have been necessary (with an a error
of 0.05 and a b error of 0.15) to show a decrease in the median
time to defervescence from 96 to 60 h in the vancomycin arm.
Thus, a total sample size of 226 assessable patients was required.
On the basis of our experience, we also estimated that the
proportion of febrile and granulocytopenic patients with cancer
who were suitable for randomization should have approached
45% of the total population of febrile neutropenic patients
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enrolled in the trial [12]. Therefore, we planned to enroll ∼500
patients to be able to randomize ∼250 patients. However, dur-
ing the study, it became clear that only 20% of the enrolled
patients were actually eligible for randomization. For this rea-
son, we first extended the study period from 24 to 30 months
and then decided to close the study, but this decision was not
driven by treatment-arm comparisons. On the basis of the
number of cases of defervescences actually observed, the power
to detect a hazard ratio of 1.6 (in other words, a decrease of
36 h in the median time to defervescence) decreased from 85%
to 78%.
Statistical evaluation of treatment response. Definitions
of febrile episodes and additional infections, clinical assess-
ments, toxicity, and microbiological methods have been de-
scribed previously [12]. Death was attributed to infection when
it occurred as a direct consequence of either the presenting
infection or an additional infection. All case reports were re-
viewed by the Data Review Committee of the EORTC-IATG
for completeness, accuracy, eligibility criteria, and assessment
of the outcome variables.
The primary end point of efficacy was the time to defer-
vescence after randomization. Defervescence or resolution of
fever was defined as a period of 3 complete days with a tem-
perature of !38C. Other end points were the number of pa-
tients who defervesced during receipt of the protocol regimen,
the number of patients who remained febrile on day 6 after
initiation of the protocol regimen, the number of patients who
had additional episodes of gram-positive bacteremia, and the
number of patients who received amphotericin B for persistent
fever. The distribution of the time to defervescence in the 2
groups was estimated by the nonparametric Kaplan-Meier
method. The 2 curves were then compared using a 2-tailed
log-rank test; the 95% CIs for the median duration of fever before
defervescence were calculated by the Brookmeyer-Crowley
method. Comparisons between proportions were performed us-
ing x2 tests (with continuity correction) or Fisher’s exact test
(when required because of the sample size).
Therapeutic regimens. P-T therapy was administered at a
dosage of 4.5 g q6h intravenously to adults and to children
who weighed 150 kg. In smaller children, P-T was administered
at a dosage of 80 mg/10 mg/kg q6h. Vancomycin was admin-
istered at a dosage of 15 mg/kg q12h (maximum daily dose, 2
g). The placebo was composed of a saccharose solution. Van-
comycin and placebo were both stored in amber-colored bottles
and administered via amber-colored syringes. Infusion time of
either preparation was at least 1 h.
Randomized patients received P-T therapy plus vancomycin
therapy or placebo for complete resolution of fever and/or of
infection for a minimum of 4 consecutive days. If the patient
was persistently febrile 4 full days after randomization (day 6
after enrollment), the protocol treatment regimen was stopped
and the patient was treated at the discretion of the investigator.
Patients enrolled in the trial were followed-up during the du-
ration of their stay in the hospital. Blinding was maintained
until all case report forms had been reviewed by the Data
Review Committee of the EORTC. The study was approved by
the Protocol Review Committee of the EORTC and by the
ethical committees at each participating institution. Informed
consent was provided by all patients who fulfilled the inclusion
criteria.
RESULTS
A flowchart describing the whole study is provided in figure
1. Briefly, from December 1997 through June 2000, 859 febrile
neutropenic patients with cancer were enrolled in the study to
receive P-T monotherapy. Of these patients, 96 were ineligible
for several reasons, including having an expected short course
of neutropenia or no neutropenia ( ), no cancer (np 65 np
), or no fever ( ); previous inclusion in the trial (10 np 6 np
); presence of a lung infiltrate ( ); and other reasons5 np 5
( ). Between hours 48 and 60 after the initiation of P-Tnp 5
monotherapy, we determined that, of the remaining 763 pa-
tients, 598 were not eligible for randomization in the double-
blind study. Of these 598 patients, 422 were no longer febrile,
129 had documented infections incompatible with randomi-
zation (gram-negative bacteremias in 90 [13], P-T resistant
gram-positive bacteremias in 17, catheter-related infections in
10, lung infiltrates in 9, viral infections in 2, fungal infection
in 1), and 47 had other exclusion criteria (modification of the
antibiotic regimen for 25 patients, neutropenia clearance in 12,
dropout toxicity for 5, and other criteria for 5).
After 48–60 h of P-T monotherapy, 165 eligible patients were
randomized to receive either vancomycin therapy ( ) ornp 86
placebo ( ), in addition to P-T therapy. The median in-np 79
terval between the initiation of empirical P-T therapy and the
first infusion of vancomycin therapy or placebo was 58 h in
both groups. There were no significant differences between the
groups in any demographic characteristics (table 1). In partic-
ular, the 2 groups were well balanced with respect to underlying
disease, duration of neutropenia, and documentation of infec-
tion. Fevers of unknown origin accounted for the majority of
febrile episodes (62 patients in the vancomycin group and 58
patients in the placebo group). Clinically documented infec-
tions (14 in the vancomycin group and 13 in the placebo group)
included mucositis (8 in the vancomycin group and 6 in the
placebo group), gastrointestinal infection (1 in the vancomycin
group and 4 in the placebo group), respiratory tract infection
(1 in the vancomycin group and 3 in the placebo group), per-
ianal infection (3 in the vancomycin group), and skin and soft
tissue infection (1 in the vancomycin group). Most of the cases
of bacteremia were due to viridans streptococci susceptible to
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Figure 1. Flowchart illustrating the study design. CDI, clinically documented infection; FUO, fever of unknown origin; P/T, piperacillin-tazobactam;
+, positive; , negative.
P-T and vancomycin (9 of 10 patients and 6 of 8 patients in
the vancomycin and placebo groups, respectively). Other gram-
positive bacteria susceptible to P-T and vancomycin that were
recovered from bacteremic patients were coagulase-negative
staphylococci ( ), Enterococcus faecalis ( ), and Mi-np 3 np 2
crococcus species ( ) (3 of whom had polymicrobial gram-np 1
positive bacteremia).
After randomization, resolution of fever was observed in 82
(95%) of 86 patients and 73 (92%) of 79 patients in the van-
comycin and placebo groups, respectively ( ) (table 2).Pp .52
This occurred without any modification to the therapy ad-
ministered to 42 patients (49%) who received vancomycin ther-
apy and to 36 patients (46%) who received placebo ( ).Pp .79
The most frequent modification was the addition of a glyco-
peptide after the administration of vancomycin therapy or pla-
cebo was stopped: indeed, open-label vancomycin or teico-
planin therapy was added to the treatment regimen for 36
patients (42%) in the vancomycin group and for 34 patients
(43%) in the placebo group ( ). The median time to de-Pp 1
fervescence after the addition of vancomycin therapy or placebo
was 3.5 days (95% CI, 2.7–4.4) in the vancomycin group and
4.3 days (95% CI, 3.5–5.1) in the placebo group, with a dif-
ference that was not statistically significant ( ; figure 2).Pp .75
Using data for the placebo arm as a reference, we estimated
the hazard ratio between the 2 distributions to be 1.03 (95%
CI, 0.75–1.43).
Likewise, there was no significant difference between the 2
treatment groups when the analysis was restricted to 142 pa-
tients (76 in the vancomycin group and 66 in the placebo
group) who received the allocated regimen for 4 full days after
randomization. The median time to defervescence was 3.1 days
(95% CI, 2.3–4.0) and 4.0 days (95% CI, 3.3–4.7) in the van-
comycin and placebo groups, respectively ( ). AdditionalPp .91
episodes of gram-positive bacteremia occurred in 7 patients, 3
of which were caused by Staphylococcus aureus, Enterococcus
species, and Corynebacterium species in the vancomycin group
and 4 of which were caused by coagulase-negative staphylococci
(in 3 patients) and S. aureus (in 1 patient) in the placebo group;
all gram-positive bacteria were susceptible to vancomycin. Fi-
nally, the rate of addition of amphotericin B to the therapeutic
regimen was similar in both groups: 31 (36%) of 86 patients
and 30 (38%) of 79 patients received amphotericin B in the
vancomycin and placebo groups, respectively.
Overall mortality rates did not differ significantly between the
2 groups ( ). Death was reported for 12 (7%) of 165Pp .23
randomized patients. Four (5%) of 86 patients who received
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Table 1. Demographic and clinical characteristics of neutropenic patients with can-
cer and persistent fever who were randomized in the vancomycin-placebo study.
Characteristic
Patients who received
piperacillin-tazobactam
therapy plus
Vancomycin therapy
(n p 86)
Placebo
(n p 79)
Adults 81 75
Age, median years (range) 42 (4–76) 42 (4–78)
Underlying disease
Acute leukemia 53 (62) 48 (61)
Lymphoma or Hodgkin disease 31 (36) 26 (33)
Other 2 (2) 5 (6)
Transplantation-associated
Stem cell or autologous 20 (23) 20 (25)
Allogenic 4 (5) 5 (6)
Neutropenia
Duration, mean days  SD (range) 18  1.6 (5–74) 18  1.7 (5–69)
Neutrophil count,a median cells/mm3 (range) 20 (0–816) 30 (0–620)
Oral prophylaxis received
Fluoroquinolone 26 (30) 26 (33)
Cotrimoxazole 6 (7) 5 (6)
Antifungal 34 (40) 35 (44)
Antiviral 23 (27) 20 (25)
Documentation of febrile episode
Gram-positive bacteremia 10 (12) 8 (10)
Clinically documented infection 14 (16) 13 (16)
Fever of unknown origin 62 (72) 58 (73)
Type of iv line received before onset of fever 66 (77) 65 (82)
Peripheral 16 18
Central 32 28
Port-a-Cath or Hickman 18 19
NOTE. Data are no. or no. (%) of patients, unless otherwise indicated.
a At the time of enrollment in the study.
vancomycin therapy died between days 14 and 31 after study
entry; death was due to infection in 1 (gram-negative bacteremia
[death occurred on day 14]), to extensive cancer in 2, and to
hemorrhage in 1. Eight (10%) of 79 placebo-treated patients died
between days 7 and 35; death was due to infection in 2 (gram-
negative bacteremia complicated by acute respiratory distress
syndrome [death on day 15] and diffuse peritonitis with pseu-
domembranous colitis complicated by acute respiratory distress
syndrome [death on day 35]). The other causes of death were
hemorrhage and extensive cancer in 3 patients each.
In the vancomycin group, adverse events definitely or prob-
ably associated with antibiotics were reported in 9 (10%) of 86
patients: rash occurred in 3 patients, pruritus in 2, nephrotox-
icity in 2, swelling of the lips in 1, and red man syndrome in
1. In the placebo group, adverse events definitely or probably
associated with antibiotics were reported in 3 (4%) of 79 pa-
tients and included pseudomembranous colitis, diarrhea, and
rash. The difference in the occurrence of adverse events was
not statistically significant between the 2 groups ( ).Pp .14
DISCUSSION
The empirical modification, merely on the basis of persistent
fever, of the antibacterial therapy regimen for neutropenic pa-
tients has become very popular in hematological centers. The
most frequent modification is the addition of a glycopeptide.
For example, in a previous EORTC-IATG trial, 28% of the
patients received a glycopeptide on the basis of persistent fever
[3]. In 2 other studies, the percentage of patients who received
empirical addition of vancomycin therapy were 26% [1] and
31% [14]. This broad administration of glycopeptides is of
concern, given the emergence of vancomycin-resistant gram-
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Table 2. Resolution of fever and time to defervescence in randomized neutropenic
patients with cancer and persistent fever (intent-to-treat population).
Variable
Patients who received
piperacillin-tazobactam
therapy plus
Vancomycin therapy
(n p 86)
Placebo
(n p 79)
Fever resolveda 82 (95) 73 (92)
Fever resolved during receipt of protocol therapya 42 (49) 36 (46)
Fever resolved after change of protocol therapya 40 (47) 37 (47)
Fever did not resolve 4 (5) 6 (8)
Fever presentb 38 (44) 41 (52)
Time to defervescence, median days (95% CI)a 3.5 (2.7–4.4) 4.3 (3.5–5.1)
NOTE. Data are no. (%) of patients, unless otherwise indicated.
a .P 1 .5
b At day 6 after initiation of protocol therapy (with or without change of antibiotic treatment).
positive cocci [15]. No study has ever documented the benefit
of this practice, and we decided to implement a prospective,
randomized, clinical trial comparing the efficacy of vancomycin
therapy with that of placebo for treating persistently febrile
neutropenic patients. Given that, in a retrospective analysis of
a previous trial, the median additional time to defervescence
among patients still febrile after 2 days of empirical therapy
was 4 days, we estimated that a constant hazard reduction of
1.6, corresponding to a reduction of at least 1.5 days, would
have been necessary to justify the addition of vancomycin [12].
In the present study, the addition of vancomycin to the treat-
ment regimen resulted in an estimated hazard ratio of 1.03 and
a 95% CI of 0.75–1.43. A constant hazard ratio of 1.43 cor-
responds to a decrease in the median time to defervescence in
the vancomycin arm of ∼30 h. This means that a decrease of
1.5 days, which is a priori considered to be a clinically mean-
ingful reduction, is unlikely to occur. In the absence of a benefit
to the main end point of efficacy, these data suggest that, despite
the reduced size of the expected sample size and the consecutive
reduction of the power of the trial from 85% to 78%, the
empirical addition of vancomycin therapy to the treatment reg-
imen for persistently febrile patients is not justified. This con-
clusion is also supported by the fact that the proportions of
patients who defervesced during receipt of protocol therapy
were similar in the 2 arms and the fact that there was no
reduction in the number of additional episodes of gram-pos-
itive bacteremia and the percentage of patients for whom am-
photericin B was empirically added to their treatment regimen.
In contrast to our previous experience, only 20% of patients
enrolled in the P-T monotherapy study were eligible for inclu-
sion in the double-blind part of the study, resulting in a lower-
than-expected randomization rate [12]. This was likely due to
the narrow window of time (between the 48th and the 60th
hour after the onset of fever) allowed for randomization. Pro-
longing the time window for randomization (to the 72nd or
96th hour) would have prevented physicians from empirically
adding amphotericin B to the regimen within a reasonable time
frame, an option that was considered unacceptable by the ma-
jority of the participating institutions.
A recent smaller study assessed the efficacy of the addition
of a glycopeptide to the treatment regimen for neutropenic
patients with persistent fever [16]. After 72–96 h of imipenem
monotherapy, 114 patients were randomized to receive either
teicoplanin or placebo. The number of patients who deferves-
ced within 72 h after randomization was similar in both groups
(44.6% in the teicoplanin group vs. 46.6% in the placebo
group), but the time to defervescence was not reported.
In view of data supporting the association between vanco-
mycin use and the increase of vancomycin-resistant enterococci
in US hospitals, the Hospital Infection Control Practice Ad-
visory Committee has developed recommendations for prudent
glycopeptide administration by clinicians [17–19]. In particular,
this committee has published a list of situations in which the
prescription of vancomycin should be discouraged. Thus, the
data provided by these 2 trials are sufficient to add to this list
the empirical addition of glycopeptides to the treatment course
for persistently febrile patients without documented gram-
positive infection. After the description of the first clinical iso-
late of S. aureus fully resistant to vancomycin, restricted use of
glycopeptides is urgently required [15].
In conclusion, with a statistical power of 78% to detect a
difference between the 2 study arms, the present study failed
to demonstrate that the empirical addition of vancomycin ther-
apy is of benefit to persistently febrile and granulocytopenic
patients with cancer and without lung infiltrates, septic shock,
clinically documented infections likely due to gram-positive
bacteria (catheter-related or skin and soft-tissue infections), and
documentation of gram-positive bacterial infections resistant
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Figure 2. Time to defervescence in patients randomized to receive vancomycin therapy or placebo. The observation was censored for all patients
who did not defervesce (4 in the vancomycin group and 6 in the placebo group). Time 0 indicates the date of administration of vancomycin therapy
or placebo.
to P-T. Because healthy persons can be colonized by vanco-
mycin-resistant enterococci, the indiscriminate administration
of glycopeptides might exert selective pressure on the intestinal
flora [20]. Therefore, appropriate administration of glycopep-
tides should help to decrease the emergence of glycopeptide-
resistant gram-positive bacteria [21].
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